Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

HKG:2566 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 12, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	2,316	1,620	-	-	-
Enterprise Value	1,880	1,716	-	-	-
Last Close Price	9.59	6.56	-	-	-
PE Ratio	16.09	10.98	-	-	-
PS Ratio	1.62	1.11	-	-	-
PB Ratio	1.32	1.00	-	-	-
P/TBV Ratio	1.50	1.00	-	-	-
P/FCF Ratio	20.61	19.10	-	-	-
P/OCF Ratio	17.64	16.06	-	-	-
EV/Sales Ratio	1.31	1.18	-	-	-
EV/EBITDA Ratio	10.45	8.38	-	-	-
EV/EBIT Ratio	13.87	10.27	-	-	-
EV/FCF Ratio	16.73	20.24	-	-	-
Debt / Equity Ratio	0.12	0.08	0.19	0.29	0.28
Debt / EBITDA Ratio	1.15	0.62	0.96	2.70	1.32
Debt / FCF Ratio	1.84	1.52	1.46	-	15.02
Asset Turnover	0.75	0.85	1.02	0.94	-
Inventory Turnover	1.55	1.80	1.74	1.45	-
Quick Ratio	3.96	3.66	1.88	1.62	1.34
Current Ratio	4.50	4.13	2.42	2.13	1.87
Return on Equity (ROE)	9.48%	11.47%	14.39%	8.07%	-
Return on Assets (ROA)	4.45%	6.08%	6.81%	2.39%	-
Return on Invested Capital (ROIC)	8.90%	13.13%	13.48%	5.51%	15.36%
Return on Capital Employed (ROCE)	7.20%	9.90%	14.30%	5.40%	16.60%
Earnings Yield	5.84%	9.11%	-	-	-
FCF Yield	4.85%	5.24%	-	-	-
Dividend Yield	0.63%	0.91%	-	-	-
Payout Ratio	1.26%	-	-	20.04%	-
Buyback Yield / Dilution	-13.46%	-2.11%	-	-	-
Total Shareholder Return	-12.85%	-1.21%	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.